Long-term follow-up of patients treated with glatiramer acetate: a multicentre,multinational extension of the European/Canadian double-blind,placebo-controlled,MRI-monitored trial

Abstract

Glatiramer acetate (GA) is effective in reducing clinical and magnetic resonance imaging (MRI) activity in relapsing-remitting multiple sclerosis (RRMS). Serial long-term MRI data are lacking for large cohorts of GA-treated patients. The European/Canadian GA study consisted of two consecutive phases, each lasting nine months. The first treatment phase was randomized, double-blind and placebo-controlled. The second was an open-label, active treatment phase with daily administration of 20 mg GA subcutaneously for all patients. For the long-term follow-up (LTFU), dual echo, pre- and postgadolinium T1-weighted brain MRI scans were obtained with the same acquisition scheme as for the original trial and a neurological assessment was performed. Lesion volumes, normalized brain volumes and percentage brain volume changes (PBVC) were measured. One hundred and forty-two (63.4%) of the 224 patients who completed the two phases of the European/Canadian study underwent the LTFU after a mean period of 5.8 years (range: 5.3-6.4); 73 were treated with GA from study initiation. MRI measures at LTFU did not significantly differ between patients originally assigned to placebo and those who were always treated with GA, but the proportion of patients who did not require walking aids at LTFU was lower in the latter group (P=0.034). PBVC between baseline and LTFU was significantly correlated with lesion load at study entry. An earlier initiation of GA treatment in patients with active RRMS might, at least partially, have a favourable impact on long-term disease evolution. Multiple Sclerosis 2007; 13: 502-508. http://msj.sagepub.com

Keywords

brain atrophy disability glatiramer acetate long-term follow-up magnetic resonance imaging multiple sclerosis

Get full access to this article

View all access options for this article.

References

Mezzapesa D. , Rovaris M. , Filippi M. Glatiramer acetate in multiple sclerosis. Exp Rev Neurotherapeutics 2005; 5: 451-58 .

Bornstein M. , Miller A. , Slagle S. , Weitzman M. , Crystal H. , Drexler E. et al. A pilot trial ofl Cop-1 in exacerbating-remitting multiple sclerosis . N Engl J Med 1987; 317: 408-14 .

Johnson KP , Brooks BR , Cohen JA , Ford CC , Goldstein J. , Lisak RP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: results ofl a phase III multicenter, double-blind, placebo-controlled trial . Neurology 1995; 45: 1268-76 .

Johnson KP , Brooks BR , Cohen JA , Ford CC , Goldstein J. , Lisak RP et al. Extended use ofl glatiramer acetate (Copaxone) is well tolerated and maintains its clinical eflflect on multiple sclerosis relapse rate and degree ofl disability . Neurology 1998; 50: 701-708 .

Comi G. , Filippi M. , Wolinsky JS and the European / Canadian Glatiramer Acetate Study Group. European/ Canadian multicenter, double-blind, randomized, placebo-controlled study ofl the eflflects ofl glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290-97 .

Johnson KP , Brooks BR , Ford CC , Goodman A. , Guarnaccia J. , Lisak RP et al. Sustained clinical benefits ofl glatiramer acetate in relapsing multiple sclerosis patients observed flor 6 years . Mult Scler 2000; 6: 255-66 .

Johnson KP , Ford CC , Lisak RP , Wolinsky JS Neurologic consequence ofl delaying glatiramer acetate therapy flor multiple sclerosis: 8-year data . Acta Neurol Scand 2005; 111: 42-47 .

Ford CC , Johnson KP , Lisak RP , Panitch HS , Shifronis G. , Wolinsky JS and the Copaxone Study Group. A prospective open-label study ofl glatiramer acetate: over a decade ofl continuous use in multiple sclerosis patients . Mult Scler 2006; 12: 309-20 .

Mancardi GL , Sardanelli F. , Parodi RC , Melani E. , Capello E. , Inglese M. et al. Eflflect ofl copolymer-1 on serial gadolinium -enhanced MRI in relapsing remitting multiple sclerosis . Neurology 1998; 50: 1127-33 .

10.

Ge Y. , Grossman RI , Udupa JK , Fulton J. , Constantinescu CS , Gonzales-Scarano F. et al. Glatimerar acetate (Copaxone) treatment in relapsing-remitting MS. Quantitative MR assessment . Neurology 2000; 54: 813-17 .

11.

Wolinsky JS , Comi G. , Filippi M. , Ladkani D. , Shifroni G and the European / Canadian Glatiramer Acetate Study Group. Copaxone's eflflect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology 2002; 59: 1284-86 .

12.

Filippi M. , Rovaris M. , Rocca MA , Sormani MP , Wolinsky JS , Comi G. et al. Glatiramer acetate reduces the proportion ofl new MS lesions evolving into black holes . Neurology 2001; 57: 731-33 .

13.

Wolinsky JS , Narayana PA , Johnson KP and the Copolymer 1 Multiple Sclerosis Study Group and the MRI Analysis Center. United States open-label glatiramer acetate extension trial flor relapsing multiple sclerosis: MRI and clinical correlates. Mult Scler 2001; 7: 33-41 .

14.

Rovaris M. , Comi G. , Rocca MA , Wolinsky JS , Filippi M and the European / Canadian Glatiramer Acetate Study Group. Short term brain volume change in relapsing-remitting multiple sclerosis: eflflect ofl glatiramer acetate and implications. Brain 2001; 124: 1803-12 .

15.

Sormani MP , Rovaris M. , Valsasina P. , Wolinsky JS , Comi G. , Filippi M. Measurement error ofl two diflflerent techniques flor brain atrophy assessment in multiple sclerosis . Neurology 2004; 62: 1432-34 .

16.

Lublin FD , Reingold SC , National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course ofl multiple sclerosis: results ofl an international survey. Neurology 1996; 46: 907-11 .

17.

Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52 .

18.

Smith SM , De Stefano N. , Jenkinson M. , Matthews P. Normalized accurate measurement ofl longitudinal brain change . J Comput Assist Tomogr 2001; 25: 466-75 .

19.

Smith SM , Zhang Y. , Jenkinson M. , Chen J. , Matthews PM , Federico A. et al. Accurate, robust and automated longitudinal and cross-sectional brain change analysis . NeuroImage 2002; 17: 479-89 .

20.

Miller DH , Barkhof F. , Frank JA , Parker GJ , Thompson AJ Measurement ofl atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance . Brain 2002 ; 125: 1676-95 .

21.

Haas J. and Firzlaff M. Twenty-flour comparison ofl immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interflerons or glatiramer acetate (Copaxone® ) . Eur J Neurol 2005; 12: 425-41 .

22.

Filippi M. , Horsfield MA , Ader HJ , Barkhof F. , Bruzzi P. , Evans A. et al. Guidelines flor using quantitative measures ofl brain magnetic resonance imaging abnormalities in monitoring the treatment ofl multiple sclerosis . Ann Neurol 1998; 43: 499-506 .

23.

Brex PA , Ciccarelli O. , O'Riordan JI, Sailer M. , Thompson AJ , Miller DH A longitudinal study ofl abnormalities on MRI and disability flrom multiple sclerosis . N Engl J Med 2002; 346: 158-64 .

24.

Rovaris M. , Agosta F. , Sormani MP , Inglese M. , Martinelli V. , Comi G. et al. Conventional and magnetization transfler MRI predictors ofl clinical multiple sclerosis evolution: a medium-term flollow-up study . Brain 2003; 126: 2323-32 .

25.

Inglese M. , Benedetti B. , Filippi M. The relation between MRI measures ofl inflammation and neurodegeneration in multiple sclerosis . J Neurol Sci 2005; 233: 15-19 .

26.

Chard DT , Brex PA , Ciccarelli O. , Griffin CM , Parker GJ , Dalton C. et al. The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year flollow up study . J Neurol Neurosurg Psychiatry 2003; 74: 1551-54 .

27.

Richert ND , Howard T. , Frank JA , Stone R. , Ostuni J. , Ohayon J. et al. Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis . Neurology 2006; 66: 551-56 .